BRAFV600E mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer

Modern Pathology

Volumn 23, Issue 8, 2010, Pages 1052-1060

  Zerilli, Monica ^a   Zito, Giovanni ^a   Martorana, Anna ^a   Pitrone, Maria ^a   Cabibi, Daniela ^a   Cappello, Francesco ^a   Giordano, Carla ^a   Rodolico, Vito ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

BRAFV600E mutation; hypoxia inducible factor 1a; MAP kinase pathway; papillary thyroid carcinoma

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, PAPILLARY; ADOLESCENT; ADULT; AGED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; THYROID NEOPLASMS; THYROIDECTOMY; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77955176654     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.86     Document Type: Article

References (34)

1. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
2. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
3. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008;15:191-205.
4. Liu D, Liu Z, Condouris S, et al. BRAF V600E maintains proliferation, transformation, and tumori-genicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007;92:2264-2271.
5. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-262.
6. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53856 cases of thyroid carcinoma treated in the U.S. 1985-1995. [see comments]. Cancer 1998;83:2638-2648.
7. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006;91:3667-3670.
8. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762.
9. Lim JH, Lee ES, You HJ, et al. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004;23:9427-9431.
10. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
11. Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer 2003;2:23.
12. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005;37:535-540.
13. Zhong H, De Marzo AM, Laughner E, et al. Over-expression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5835.
14. Kumar SM, Yu H, Edwards R, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 2007;67:3177-3184.
15. Burrows N, Resch J, Cowen R, et al. Expression of hypoxia inducible factor 1{alpha} in thyroid carcinomas. Endocr Relat Cancer 2010;17:61-72.
16. Jubb A, Hillan K. Expression of HIF-1 alpha in human tumours. J Clin Pathol 2005;58:1344.
17. Scarpino S, Cancellario d'Alena F, Di Napoli A, et al. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 2004;202:352-358.
18. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-225.
19. Preto A, Goncalves J, Rebocho AP, et al. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 2009;9:387.
20. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
21. Jarry A, Masson D, Cassagnau E, et al. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 2004;18: 349-352.
22. Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid o or/1cm and their paired lymph node metastases. Cancer 2007;110:1218-1226.
23. DeLellis RA, Lloyd RV, Heitz PU, et al. (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon, France, 2004, pp 50-57.
24. Fabien N, Fusco A, Santoro M, et al. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 1994;73:2206-2212.
25. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64:2338-2342.
26. Hellemans J, Mortier G, De Paepe A, et al. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:19.
27. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006;5:2.
28. Salvatore G, De Falco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-1629.
29. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004;26:262-269.
30. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-998.
31. Semenza GL. HIF-1 and tumor progression: pathophy-siology and therapeutics. Trends Mol Med 2002;8: S62-S67.
32. Ahmed SI, Thomas AL, Steward WP. Vascular en-dothelial growth factor (VEGF) inhibition by small molecules. J Chemother 2004;16:59-63.
33. Moeller BJ, Dewhirst MW. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 2004;3:1107-1110.
34. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.